SCHEMBL3016860

SCHEMBL3016860

O=S(=O)(c1ccc(Cl)c(Cl)c1)C1CCN(c2nc(Cc3ccc(F)c(Cl)c3)cs2)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.36
LMNA P02545 1/20 0.36
HTR2A P28223 2/20 0.36
HTR2C P28335 2/20 0.36
KCNH2 Q12809 2/20 0.36
DRD2 P14416 1/20 0.36
AR P10275 1/20 0.35
TRPV1 Q8NER1 2/20 0.35
CYP19A1 P11511 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
MAPT P10636 1/20 0.34
ALDH1A1 P00352 1/20 0.34
PKM P14618 1/20 0.34
PKLR P30613 1/20 0.34
SCN1A P35498 1/20 0.34
SCN8A Q9UQD0 1/20 0.34
SOS1 Q07889 2/20 0.33
EPHX2 P34913 1/20 0.33
GAA P10253 1/20 0.33
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011357 1.00 L3MBTL1 (0.36) L3MBTL1LMNAHTR2AHTR2CKCNH2
SCHEMBL3009255 0.97 HTR2A (0.37) L3MBTL1HTR2AHTR2CKCNH2DRD2
SCHEMBL3004485 0.94 HTR2A (0.36) L3MBTL1HTR2AHTR2CKCNH2DRD2
SCHEMBL3007633 0.94 CACNA1G (0.36) L3MBTL1LMNAHTR2AHTR2CKCNH2
SCHEMBL3013801 0.94 L3MBTL1 (0.39) L3MBTL1LMNAHTR2AARTRPV1
SCHEMBL3014991 0.94 CACNA1G (0.36) L3MBTL1HTR2AHTR2CKCNH2DRD2
SCHEMBL3014833 0.94 L3MBTL1 (0.35) L3MBTL1LMNAHTR2AHTR2CKCNH2
SCHEMBL3018344 0.93 HTR2A (0.41) L3MBTL1LMNAHTR2AHTR2CKCNH2
SCHEMBL3022387 0.93 HTR2A (0.43) L3MBTL1LMNAHTR2AHTR2CKCNH2
SCHEMBL3021363 0.92 HTR2A (0.42) L3MBTL1HTR2AHTR2CKCNH2DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA L3MBTL1 1847/4885LMNA 80/4885HTR2A 752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.